Can Alveolar-Arterial Difference and Lung Ultrasound Help the Clinical Decision Making in Patients with COVID-19?

Gianmarco SeccoFrancesco SalinaroCarlo BellazziMarco La SalviaMarzia DelorenzoCaterina ZatteraBruno BarcellaFlavia RestaGiulia VezzoniMarco BonzanoGiovanni CappaRaffaele BrunoIvo CasagrandaStefano Perlini

Published in: Diagnostics (Basel, Switzerland) (2021)

LUS and AaDO2 are easy and effective tools, which allow bedside risk stratification in patients with COVID-19, especially when P/F values, signs, and symptoms are not indicative of severe lung dysfunction.

Keyphrases

magnetic resonance imaging
oxidative stress
early onset
computed tomography